2 results about "Suspension Dosage Form" patented technology

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.

The present disclosure provides an oral suspension of allopurinol suitable for administration to pediatric, geriatric patients, as well as to patients experiencing difficulty in swallowing solid dosage forms. The suspension is stable, palatable and safer compared to compounded suspensions of allopurinol. The suspension dosage form of allopurinol also allows for a more accurate dosing. The suspension is stable for at least 24 months at room temperature, demonstrating low impurity formation under storage conditions.